Dehydroepiandrosterone (DHEA): Hypes and hopes

Drugs

Volumn 74, Issue 11, 2014, Pages 1195-1207

  Rutkowski, Krzysztof ^a   Sowa, Paweł ^b   Rutkowska Talipska, Joanna ^b   Kuryliszyn Moskal, Anna ^b   Rutkowski, Ryszard ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; GENAFLOW; PRASTERONE; PRASTERONE SULFATE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR DELTA CHAIN; TESTOSTERONE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; AGING; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG STRUCTURE; FERTILITY; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; NONHUMAN; REVIEW; SEXUAL SATISFACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH2 CELL; VAGINA ATROPHY; VASODILATATION; ANIMAL; BLOOD; BONE DENSITY; CHEMISTRY; DRUG EFFECTS; HYPERSENSITIVITY; PHYSIOLOGY;

ADRENAL INSUFFICIENCY; AGING; ANIMALS; BONE DENSITY; DEHYDROEPIANDROSTERONE; DIETARY SUPPLEMENTS; HUMANS; HYPERSENSITIVITY;

EID: 84904666526     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0259-8     Document Type: Review

References (95)

1. Lieberman S. An abbreviated account of some aspects of the biochemistry of DHEA, 1934-1995. Ann N Y Acad Sci. 1995;774:1-15. (Pubitemid 26140356)
2. Leowattana W. DHEAS as a new diagnostic tool. Clin Chim Acta. 2004;341:1-15. (Pubitemid 38210308)
3. Gaby AR. Dehydroepiandrosterone: biological effects and clinical significance. Altern Med Rev. 1996;1:60-9. (Pubitemid 126737413)
4. Nestler JE. DHEA: a coming age. Ann N Y Acad Sci. 1995;774:IX-XI.
5. Maninger N, Wolkowitz OM, Reus VI, et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol. 2009;30:65-91.
6. Dumas de la Roque E, Quignard JF, Ducret T, et al. Beneficial effect of dehydroepiandrosterone on pulmonary hypertension in a rodent model of pulmonary hypertension in infants. Pediatr Res. 2013;74:163-99.
7. Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochem Pharmacol. 2013;85:718-26.
8. Webb SJ, Geoghegan TE, Prough RA, et al. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev. 2006;38:89-116. (Pubitemid 43739001)
9. Traish AM, Kang HP, Saad F, et al. Dehydroepiandrosterone (DHEA): a precursor steroid or an active hormone in human physiology. J Sex Med. 2011;8:2960-82.
10. Simoncini T, Mannella P, Fornari L, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and non-genomic mechanisms. Endocrinology. 2003;144:3449-55. (Pubitemid 36904421)
11. Espinoza J, Montaño LM, Perusquía M. Nongenomic bronchodilating action elicited by dehydroepiandrosterone (DHEA) in a guinea pig asthma model. J Steroid Biochem Mol Biol. 2013;138:174-82.
12. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha (i2,3). J Biol Chem. 2002;277:21379-88. (Pubitemid 34952278)
13. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004;69:279-89. (Pubitemid 38748724)
14. Simoncini T, Genazzani AR. Dehydroepiandrosterone, the endothelium, and cardio-vascular protection. Endocrinology. 2007;148:3065-7.
15. Olivo HF, Perez-Hernandez N, Liu D, et al. Synthesis and application of a photoaffinity analog of dehydroepiandrosterone (DHEA). Bioorg Med Chem Lett. 2010;20:1153-5.
16. Liu D, O'Leary B, Iruthayanathan M, et al. Evaluation of a novel photoactive and biotinylated dehydroepiandrosterone analog. Mol Cell Endocrinol. 2010;328:56-62.
17. Waschatko G, Kojro E, Zahnow M, et al. Photo-DHEA - a functional photoreactive dehydroepiandrosterone (DHEA) analog. Steroids. 2011;76:502-27.
18. Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. J Clin Pharmacol. 1999;39:327-48. (Pubitemid 29159823)
19. Olech E, Merrill JT. DHEA supplementation: the claims in perspective. Cleve Clin J Med. 2005;72:965-966, 968, 970-971.
20. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab. 1996;81:3147-51.
21. Binello E, Gordon CM. Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol. 2003;3:635-41. (Pubitemid 37451872)
22. Burkhardt T, Schmidt NO, Vettorazzi E, et al. DHEA(S): a novel marker in Cushing's disease. Acta Neurochir (Wien). 2013;155:479-84.
23. Kasperska-Zaja̧c AE, Brzoza ZK, Koczy-Baron E, et al. Dehydroepiandrosterone in therapy of allergic diseases. Recent Pat Inflamm Allergy Drug Discov. 2009;3:211-3.
24. Dhatariya KK, Nair KS. Dehydroepiandrosterone: is there a role for replacement? Mayo Clin Proc. 2003;78:1257-73. (Pubitemid 37193517)
25. Valenti G, Denti L, Saccò M, et al. GISEG (Italian Study Group on Geriatric Endocrinology), consensus document on substitution therapy with DHEA in the elderly. Aging Clin Exp Res. 2006;18:277-300. (Pubitemid 44762352)
26. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update. 2007;13:239-48. (Pubitemid 47071610)
27. Thompson RD, Carlson M, Thompson RD, et al. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int. 2000;83:847-57.
28. Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope? Hum Reprod. 2011;26:1941-4.
29. Kushnir MM, Blamires T, Rockwood AL, et al. Liquid chromatographytandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem. 2010;56:1138-47.
30. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-5. (Pubitemid 14031806)
31. Roth GS, Lane MA, Ingram DK, et al. Biomarkers of caloric restriction may predict longevity in humans. Science. 2002;297:811.
32. Celec P, Stárka L. Dehydroepiandrosterone: is the fountain of youth drying out? Physiol Res. 2003;52:397-407. (Pubitemid 37039903)
33. Allolio B, Arlt W. DHEA treatment: myth or reality? Trends Endocrinol Metab. 2002;13:288-94. (Pubitemid 36733958)
34. Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy. 2005;4:377-85. (Pubitemid 40873125)
35. Saponaro S, Guarnieri V, Pescarmona GP, et al. Long-term exposure to dehydroepiandrosterone affects the transcriptional activity of the glucocorticoid receptor. J Steroid Biochem Mol Biol. 2007;103:129-36. (Pubitemid 46149295)
36. Genazzani AD, Stomati M, Bernardi F, et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril. 2003;80:1495-501. (Pubitemid 37532468)
37. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676-81.
38. Basu R, Dalla Man C, et al. Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes. 2007;56:753-66. (Pubitemid 46348480)
39. Christiansen JJ, Bruun JM, Christiansen JS, et al. Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. Eur J Endocrinol. 2011;165:293-300.
40. Hartkamp A, Geenen R, Godaert GL, et al. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis. 2010;69:1144-7.
41. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360-7. (Pubitemid 24181005)
42. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. Ann N Y Acad Sci. 1995;774:128-42. (Pubitemid 26140365)
43. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998;49:421-32. (Pubitemid 28475333)
44. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHE Age Study to a sociobiomedical issue. Proc Natl Acad Sci. 2000;97:4279-84. (Pubitemid 30226124)
45. Weiss EP, Shah K, Fontana L, et al. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009;89:1459-67.
46. Weiss EP, Villareal DT, Fontana L, et al. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3:533-42.
47. Nouveau S, Bastien P, Baldo F, et al. Effects of topical DHEA on aging skin: a pilot study. Maturitas. 2008;59:174-81.
48. El-Alfy M, Deloche C, Azzi L, et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? Br J Dermatol. 2010;163:968-76.
49. Shin MH, Rhie GE, Park CH, et al. Modulation of collagen metabolism by the topical application of dehydroepiandrosterone to human skin. J Invest Dermatol. 2005;124:315-23. (Pubitemid 40175877)
50. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341:1013-20. (Pubitemid 29451796)
51. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93:400-9. (Pubitemid 351240809)
52. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005;54:765-9. (Pubitemid 40322080)
53. +) T cells. Eur J Immunol. 2005;35:3694-703.
54. Chang DM, Lan JL, Lin HY, et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:2924-7.
55. Petri MA, Lahita RG, Van Vollenhoven RF, et al. GL601 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46:1820-9. (Pubitemid 34774514)
56. Andus T, Klebl F, Rogler G, et al. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003;17:409-14. (Pubitemid 36259403)
57. Altman R, Motton DD, Kota RS, et al. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol. 2008;48:76-84.
58. Bonnet S, Paulin R, Sutendra G, et al. Dehydroepiandrosterone reverses systemic vascular remodelling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation. 2009;120:1231-40.
59. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health: National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95:4985-92.
60. Yu CK, Yang BC, Lei HY, et al. Attenuation of house dust mite Dermatophagoides farinae-induced airway allergic responses in mice by dehydroepiandrosterone is correlated with down-regulation of TH2 response. Clin Exp Allergy. 1999;29:414-22. (Pubitemid 29145145)
61. Lin XH, Choi IS, Koh YA, et al. Effects of combined bacille Calmette-Guérin and dehydroepiandrosterone treatment on established asthma in mice. Exp Lung Res. 2009;35:250-61.
62. Liou CJ, Huang WC. Dehydroepiandrosterone suppresses eosinophil infiltration and airway hyperresponsiveness via modulation of chemokines and Th2 cytokines in ovalbumin-sensitized mice. J Clin Immunol. 2011;31:656-65.
63. Choi IS, Cui Y, Koh YA, et al. Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics. Korean J Intern Med. 2008;23:176-81.
64. Shin YS, Takeda K, Gelfand EW. Understanding asthma using animal models. Allergy Asthma Immunol Res. 2009;191:10-8.
65. Tabata N, Tagami H, Terui T. Dehydroepiandrosterone may be one of the regulators of cytokine production in atopic dermatitis. Arch Dermatol Res. 1997;289:410-4.
66. Koziol-White CJ, Goncharova EA, Cao G, et al. DHEA-S inhibits human neutrophil and human airway smooth muscle migration. Biochim Biophys Acta. 2012;1822:1638-42.
67. Wenzel SE, Robinson CB, Leonard JM, et al. Nebulized dehy- droepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study. Allergy Asthma Proc. 2010;31:461-71.
68. Chan CC, Liou CJ, Xu PY, et al. Effect of dehydroepiandrosterone on atopic dermatitis-like skin lesions induced by 1-chloro-2,4-dinitrobenzene in mouse. J Dermatol Sci. 2013;72:149-57.
69. Kasperska-Zajac A, Brzoza Z, Rogala B. Lower serum concentration of dehydroepiandrosterone sulphate in patients suffering from chronic idiopathic urticaria. Allergy. 2006;61:1489-90. (Pubitemid 44665320)
70. Kasperska-Zajac A, Brzoza Z, Rogala B. Serum concentration of dehydroepiandrosterone sulphate in female patients with chronic idiopathic urticaria. J Dermatol Sci. 2006;41:80-1. (Pubitemid 43075435)
71. Brzoza Z, Kasperska-Zajac A, Badura-Brzoza K, et al. Decline in dehydroepiandrosterone sulfate observed in chronic urticaria is associated with psychological distress. Psychosom Med. 2008;70:723-8.
72. Kasperska-Zajac A, Brzoza Z, Rogala B. Plasma concentration of interleukin 6 (IL-6), and its relationship with circulating concentration of dehydroepiandrosterone sulfate (DHEA-S) in patients with chronic idiopathic urticaria. Cytokine. 2007;39:142-6. (Pubitemid 47520707)
73. Kamel-Sabry MK, Farres MN, Melek NA, et al. Prolactin and dehydroepiandrosterone sulfate: are they related to the severity of chronic urticaria? Arch Med Res. 2013;44:21-6.
74. Blauer KL, Poth M, Rogers WM, et al. Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology. 1991;129:3174-9.
75. Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo: II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol. 1990;20:793-802. (Pubitemid 20167034)
76. Harding G, Mak YT, Evans B, et al. The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA. Cytokine. 2006;36:57-68. (Pubitemid 46049022)
77. Buoso E, Lanni C, Molteni E, et al. Opposing effects of cortisol and dehydroepiandrosterone on the expression of the receptor for Activated C Kinase 1: implications in immunosenescence. Exp Gerontol. 2011;46:877-83.
78. Kasperska-Zajac A. Asthma and dehydroepiandrosterone (DHEA): facts and hypotheses. Inflammation. 2010;33:320-4.
79. Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment: difficulties of and barriers to drug development. Lancet. 2011;378:1027-37.
80. Eusebio MO, Grzelewski T, Pietruczuk M, et al. The patents on glucocorticosteroids and selected new therapies for the management of asthma in children. Recent Pat Inflamm Allergy Drug Discov. 2011;5:57-65.
81. Kannisto S, Laatikainen A, Taivainen A, et al. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients. Eur J Endocrinol. 2004;150:687-90. (Pubitemid 38786539)
82. Fusi FM, Ferrario M, Bosisio C, et al. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecol Endocrinol. 2013;29:940-3.
83. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16:907-22.
84. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16:923-31.
85. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for post-menopausal women. J Clin Endocrinol Metab. 2011;96:1642-53.
86. Corona G, Rastrelli G, Giagulli VA, et al. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. J Clin Endocrinol Metab. 2013;98:3615-26.
87. Grossman A, Johannsson G, Quinkler M, et al. Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013;169:165-75.
88. Hyman JH, Margalioth EJ, Rabinowitz R, Tsafrir A, et al. DHEA supplementation may improve IVF outcome in poor responders: a proposed mechanism. Eur J Obstet Gynecol Reprod Biol. 2013;168:49-53.
89. Yilmaz N, Uygur D, Inal H, et al. Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count. Eur J Obstet Gynecol Reprod Biol. 2013;169:257-60.
90. Kara M, Aydin T, Aran T, et al. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur J Obstet Gynecol Reprod Biol. 2014;173:63-5.
91. Strauss S, Greve T, Ernst E, et al. Administration of DHEA augments progesterone production in a woman with low ovarian reserve being transplanted with cryopreserved ovarian tissue. J Assist Reprod Genet. 2014;31:645-9.
92. Sunkara SK, Pundir J, Khalaf Y. Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis. Reprod Biomed Online. 2011;22:545-55.
93. Narkwichean A, Maalouf W, Campbell BK, et al. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol. 2013;11:44.
94. ChEBI: the database and ontology of Chemical Entities of Biological Interest. Dehydroepiandrosterone (CHEBI 28689). Available from http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5881. Accessed 5 July 2014.
95. ChEBI: the database and ontology of Chemical Entities of Biological Interest. Dehydroepiandrosterone sulfate (CHEBI 16814). Available from http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=12594&loc=ec-rcs. Accessed 5 July 2014.